World News

Arcellx (NASDAQ:ACLX) Price Target Raised to $39.00

Arcellx (NASDAQ:ACLX) Price Target Raised to .00

Arcellx (NASDAQ:ACLX – Get Score) had its goal worth elevated by analysts at SVB Leerink from $35.00 to $39.00 in a analysis word issued to traders on Thursday, Benzinga studies. The agency presently has an “outperform” score on the inventory. SVB Leerink’s goal worth would counsel a possible upside of 26.58% from the inventory’s earlier shut. SVB Leerink additionally issued estimates for Arcellx’s Q1 2024 earnings at ($0.68) EPS, Q2 2024 earnings at ($0.69) EPS, Q3 2024 earnings at ($0.70) EPS and This fall 2024 earnings at ($0.59) EPS.

ACLX has been the topic of a number of different studies. Barclays boosted their goal worth on Arcellx from $25.00 to $38.00 and gave the corporate an “chubby” score in a report on Monday, December twelfth. Needham & Firm LLC restated a “purchase” score and issued a $35.00 worth goal on shares of Arcellx in a report on Thursday. Piper Sandler elevated their goal worth on Arcellx from $96.00 to $104.00 in a report on Friday, December ninth. HC Wainwright started protection on Arcellx in a report on Monday, February thirteenth. They set a “purchase” score and a $42.00 goal worth on the inventory. Lastly, Canaccord Genuity Group raised their worth goal on Arcellx from $32.00 to $34.00 in a report on Monday, December twelfth. 9 funding analysts have rated the inventory with a purchase score, In accordance with MarketBeat.com, the inventory presently has a consensus score of “Purchase” and a mean goal worth of $43.36.

Arcellx Buying and selling Up 0.9 %

ACLX opened at $30.81 on Thursday. Arcellx has a 12 month low of $6.03 and a 12 month excessive of $35.26. The inventory has a market capitalization of $1.35 billion and a price-to-earnings ratio of -0.69. The corporate has a debt-to-equity ratio of 0.11, a present ratio of 6.48 and a fast ratio of 6.48. The enterprise has a fifty day transferring common worth of $29.96 and a 200 day transferring common worth of $25.94.

Insiders Place Their Bets

In different Arcellx information, insider Christopher Heery offered 6,966 shares of the corporate’s inventory in a transaction on Thursday, February ninth. The inventory was offered at a mean worth of $30.77, for a complete worth of $214,343.82. Following the transaction, the insider now owns 15,589 shares of the corporate’s inventory, valued at $479,673.53. The transaction was disclosed in a submitting with the Securities & Change Fee, which is obtainable by means of this hyperlink. Insiders offered 10,721 shares of firm inventory price $336,182 over the past ninety days. Firm insiders personal 5.57% of the corporate’s inventory.

Hedge Funds Weigh In On Arcellx

Hedge funds have lately modified their holdings of the inventory. MetLife Funding Administration LLC boosted its holdings in Arcellx by 127.6% within the fourth quarter. MetLife Funding Administration LLC now owns 38,336 shares of the corporate’s inventory price $1,188,000 after buying a further 21,490 shares within the final quarter. Voya Funding Administration LLC boosted its holdings in Arcellx by 106.6% within the fourth quarter. Voya Funding Administration LLC now owns 112,841 shares of the corporate’s inventory price $3,496,000 after buying a further 58,220 shares within the final quarter. Lecturers Retirement System of The State of Kentucky purchased a brand new stake in Arcellx within the fourth quarter price $619,000. Alliancebernstein L.P. boosted its holdings in Arcellx by 24.2% through the fourth quarter. Alliancebernstein L.P. now owns 26,700 shares of the corporate’s inventory valued at $827,000 after buying a further 5,200 shares through the interval. Lastly, Utah Retirement Techniques purchased a brand new stake in Arcellx through the fourth quarter valued at about $799,000. 91.78% of the inventory is owned by institutional traders and hedge funds.

About Arcellx

(Get Score)

Arcellx, Inc, a clinical-stage biotechnology firm, engages within the improvement of varied immunotherapies for sufferers with most cancers and different incurable illnesses. The corporate’s lead ddCAR product candidate is CART-ddBCMA, which is in section 1 scientific trial for the remedy of sufferers with relapsed or refractory (r/r) a number of myeloma (MM).

Featured Articles

Analyst Recommendations for Arcellx (NASDAQ:ACLX)



Obtain Information & Scores for Arcellx Day by day – Enter your electronic mail tackle beneath to obtain a concise each day abstract of the most recent information and analysts’ rankings for Arcellx and associated firms with MarketBeat.com’s FREE each day electronic mail e-newsletter.

Love After Lockup Season 5: Love, Trials, and Redemption

Mugen

Gaza: Deadlock deepens as Security Council rejects resolutions by U.S., Russia

Mugen

Suspected kidnappers kill two traditional rulers in Ekiti

Mugen
dnka xsnl mcpa csnl